European Companies Search Engine
UK funding (£130,934): MRAP2 (Melanocortin Receptor Accessory Protein Two) and its role in melanocortin receptor trafficking and expression Ukri5 Sept 2006 UK Research and Innovation, United Kingdom
Overview
Text
MRAP2 (Melanocortin Receptor Accessory Protein Two) and its role in melanocortin receptor trafficking and expression
| Abstract | Familial Glucocorticoid Deficiency (FGD) is a potentially life threatening genetic disease resulting from the adrenal gland being unable to respond to a hormone, ACTH, secreted from the brain. Gene defects in the ACTH receptor have previously been described and account for 25% of cases. The Clark Laboratory has recently found another gene responsible for FGD, called MRAP (Melanocortin 2 Receptor Accessory Protein). Experiments involving MRAP have shed light on the action of ACTH in normal physiology and disease. Searching through the human genome led to the identification of a similar gene called MRAP2. The protein made from this gene has important similarities to MRAP. This MRAP2 protein is therefore likely to interact with ACTH-like receptors. We hypothesise that analyzing the function of MRAP2 will help us understand more about this family of receptors and diseases which arise when they do not function properly. |
| Category | Fellowship |
| Reference | G0600408/1 |
| Status | Closed |
| Funded period start | 05/09/2006 |
| Funded period end | 04/09/2008 |
| Funded value | £130,934.00 |
| Source | https://gtr.ukri.org/projects?ref=G0600408%2F1 |
Participating Organisations
| Queen Mary University of London |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Queen Mary University of London, London.
The visualizations for "Queen Mary University of London - UK funding (£130,934): MRAP2 (Melanocortin Receptor Accessory Protein Two) and its role in melanocortin receptor trafficking and expression"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
